e-learning
resources
Berlin 2001
Sunday 23.09.2001
COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy?
J. M. Barth, D. Jaeger, M. Broder (Halle, Marburg, Germany)
Source:
Annual Congress 2001 - COPD
Session:
COPD
Session type:
Poster Discussion
Number:
277
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. M. Barth, D. Jaeger, M. Broder (Halle, Marburg, Germany). Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy?. Eur Respir J 2001; 16: Suppl. 31, 277
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma?
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Two therapy option in patients with uncontrolled asthma
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 134s
Year: 2003
Identifying patients with severe asthma that will be benefit from biological therapy
Source: Virtual Congress 2020 – Rethinking asthma
Year: 2020
Which patients with COPD can potentially benefit from prophylactic use of antibiotics?
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007
Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
How often do asthma patients claim prescribed therapy?
Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS
Year: 2017
The clinico-immunological evaluation of the ribomunyl therapy in complex treatment of COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 674s
Year: 2006
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021
Early treatment response may predict long-term mepolizumab benefit in severe asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 49s
Year: 2005
The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Cost consequences of tiotropium plus existing therapy
versus
existing therapy alone following one year of treatment in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 5s
Year: 2001
Symptomatic burden of COPD for patients receiving dual or triple therapy
Source: International Congress 2017 – Management of COPD
Year: 2017
Lack of clinically relevant differences between combination therapy and monotherapy in COPD
Source: Eur Respir J 2014; 43: 1204
Year: 2014
Lack of clinically relevant differences between combination therapy and monotherapy in COPD
Source: Eur Respir J 2014; 43: 1204-1205
Year: 2014
Real-world treatment patterns of benralizumab therapy for patients with severe asthma
Source: Virtual Congress 2020 – Diagnosis and management of asthma
Year: 2020
Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept